Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | GLP1R | P43220 | 8/20 | 0.38 |
| ▸ | HPGD | P15428 | 4/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | NAMPT | P43490 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14683460 | 0.96 | GLP1R (0.41) | TSHRMEN1KMT2AGLP1RHPGD | |
| SCHEMBL14683581 | 0.89 | ALDH1A1 (0.40) | TSHRMEN1KMT2AGLP1RALDH1A1 | |
| SCHEMBL12118613 | 0.86 | GLP1R (0.42) | TSHRMEN1KMT2AGLP1RKDM4E | |
| SCHEMBL71147 | 0.85 | GLP1R (0.46) | TSHRMEN1KMT2AGLP1REPHX2 | |
| SCHEMBL71906 | 0.85 | MEN1 (0.45) | TSHRMEN1KMT2AGLP1REPHX2 | |
| SCHEMBL14683467 | 0.85 | GLP1R (0.44) | TSHRMEN1KMT2AGLP1RALDH1A1 | |
| SCHEMBL71315 | 0.85 | GLP1R (0.46) | TSHRMEN1KMT2AGLP1REPHX2 | |
| SCHEMBL14683527 | 0.85 | GLP1R (0.44) | TSHRMEN1KMT2AGLP1RALDH1A1 | |
| SCHEMBL12118741 | 0.84 | GLP1R (0.41) | TSHRMEN1KMT2AGLP1R | |
| SCHEMBL13805652 | 0.83 | GLP1R (0.49) | TSHRMEN1KMT2AGLP1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130035285-A1 | NOVEL GLUCAGON ANALOGUES | NOVO NORDISK A/S (DK) | 2013-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130035285-A1 | NOVEL GLUCAGON ANALOGUES | GLP1R, GIPR, IAPP | TSHR 197/4885MEN1 858/4885KMT2A 4189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.